Login / Signup

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients.

Hao ZhaoMiao-Yan ZhangKai-Ni ShenJun FengXin-Xin CaoMing-Hui DuanDao-Bin ZhouLu ZhangJian Li
Published in: Blood (2023)
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • low dose
  • high dose
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • multiple myeloma
  • patient reported outcomes